Effect of febuxisostat on serum uric acid levels and endothelial function in patients with hyperuricemia

Phase 4

• Conditions: Hyperuricemia

• Registration Number: JPRN-UMIN000008753
• Lead Sponsor: Department of Cardiovascular Medicine, Juntendo University School of Medicine

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-09-01
• Study Completion: 2014-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients who have contraindication of febuxostat treatment. 2) Patients with secondary hyperuricemia. 3) Patient who have systolic blood pressure of 160mmHg or higher, or diastolic blood pressure of 100mgHg or higher. 4) Patients with AST and ALT elevation more than twice the institutional standard. 5) Patients who have had coronary heart disease and cerebrovascular disease within 6 months. 6) Patients treated with mercaptopurine hydrate or azathioprine 7) Breast-feeding woman 8) Patients judged to be unsuitable participants by physician-in-charge

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) %change of serum uric acid levels 2) Endothelial function by Endo-PAT

Secondary Outcome Measures

Name	Time	Method
1) Oxidative stress marker (ie. nitrotyrosine, ADMA and MDA-LDL) 2) Office blood pressure (Ambulatory Blood Pressure Monitoring in possible cases)